Table 2

Summary of clinical pathologic status of non triple-negative cases (non-TNBC)
Characteristic No. of patients (%)
ER/PR+, HER2+ (N = 111) ER/PR+, HER2- (N =106) ER/PR-, HER2+ (N =81)
AGE AT DIAGNOSIS (y)
  ≤ 40 21 (18.9%) 17 (16.0%) 11 (13.6%)
  41 ≤ y ≤ 49 42 (37.8%) 45 (42.5%) 26 (32.1%)
  50 ≤ y ≤ 65 37 (33.3%) 33 (31.1%) 37 (45.7%)
  > 65 11 (9.9%) 11 (10.4%) 7 (8.6%)
HISTOLOGY
  DCIS 14 (12.6%) 13 (12.3%) 8 (9.9%)
  IDC 89 (80.2%) 74 (69.8%) 69 (85.2%)
  Others 8 (7.2%) 19 (17.9%) 4 (4.9%)
GRADE
  1 (well differentiated) 2 (1.8%) 4 (3.8%) 1 (1.2%)
  2 (moderately differentiated) 50 (45.0%) 48 (45.3%) 12 (14.8%)
  3 (poorly differentiated) 52 (46.8%) 35 (33.0%) 64 (79.0%)
  Not determined 7 (6.3%) 19 (17.9%) 4 (4.9%)
TUMOR SIZE (cm)
  ≤ 2 46 (41.4%) 44 (41.5%) 19 (23.5%)
  2 < cm ≤ 5 32 (28.8%) 27 (25.5%) 40 (49.4%)
  > 5 7 (6.3%) 2 (1.9%) 6 (7.4%)
  Not determined 26 (23.4%) 33 (31.1%) 16 (19.8%)
LYMPH NODE INFILTRATION
  Positive 34 (30.6%) 24 (22.6%) 33 (40.7%)
  Negative 75 (67.6%) 74 (69.8%) 45 (55.6%)
  Not determined 2 (1.8%) 8 (7.5%) 3 (3.7%)
p53 STATUS
  Positive 10 (9.0%) 7 (6.6%) 28 (34.6%)
  Negative 101 (91.0%) 97 (91.5%) 53 (65.4%)
  Not determined  0 (0.0%) 2 (1.9%) 0 (0.0%)

Note: Percentage (%) indicates the percentage within the subgroup. DCIS ductal carcinoma in-situ, IDC invasive ductal carcinoma.

Kanapathy Pillai et al.

Kanapathy Pillai et al. BMC Clinical Pathology 2012 12:18   doi:10.1186/1472-6890-12-18

Open Data